The sodium–glucose cotransporter 2 inhibitor ipragliflozin improves liver function and insulin resistance in Japanese patients with type 2 diabetes

Sodium–glucose cotransporter 2 inhibitor (SGLT2i) treatment is a therapeutic approach for type 2 diabetes mellitus (T2DM). Some reports have shown that SGLT2i treatment improves insulin resistance; however, few studies have evaluated insulin resistance by the glucose clamp method. Hepatic insulin cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Okura, Tsuyoshi, Fujioka, Yohei, Nakamura, Risa, Kitao, Sonoko, Ito, Yuichi, Anno, Mari, Matsumoto, Kazuhisa, Shoji, Kyoko, Matsuzawa, Kazuhiko, Izawa, Shoichiro, Okura, Hiroko, Ueta, Etsuko, Kato, Masahiko, Imamura, Takeshi, Taniguchi, Shin-ichi, Yamamoto, Kazuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8814145/
https://www.ncbi.nlm.nih.gov/pubmed/35115614
http://dx.doi.org/10.1038/s41598-022-05704-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8814145/
https://www.ncbi.nlm.nih.gov/pubmed/35115614
http://dx.doi.org/10.1038/s41598-022-05704-y

Ejemplares similares